Fresenius Kabi has announced the availability of 30 ml vials acetylcysteine inhalation solution, 20%, helping to alleviate a shortage of the product in the US. The company is marketing the inhalation solution in the US under a licensing agreement with Innopharma, whose ANDA was approved by the FDA in September 2012.
The company’s President and CEO John Ducker commented, “The introduction of acetylcysteine solution further illustrates Fresenius Kabi’s commitment to meeting market needs in the short term, while broadening the availability of our APP critical care products for the long term.” APP Pharma is the US specialty pharmaceutical division of Fresenius.
Read the Fresenius Kabi press release.
